Active substance
Conjugated estrogens
- Health Canada 5
- US price lines 4
- Safety 4
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| PREMARIN | 02414678 | 0.3 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| PREMARIN | 02414686 | 0.625 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| PREMARIN | 02414694 | 1.25 MG | TABLET (EXTENDED-RELEASE) · ORAL | PFIZER CANADA ULC |
| PREMARIN INTRAVENOUS | 02043386 | 25 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | PFIZER CANADA ULC |
| PREMARIN VAGINAL CREAM | 02043440 | 0.625 MG / G | CREAM · VAGINAL | PFIZER CANADA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CONJUGATED ESTROGENS 0.3 MG TB | $5.37279 | per EA | 23 Sep 2026 |
| US NADAC | CONJUGATED ESTROGENS 0.45 MG TB | $5.4808 | per EA | 23 Sep 2026 |
| US NADAC | CONJUGATED ESTROGENS 0.9 MG TB | $5.57252 | per EA | 23 Sep 2026 |
| US NADAC | CONJUGATED ESTROGENS 1.25 MG TB | $5.47658 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- EMA PRAC 14 May 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: Yes - EMA PRAC 12 Mar 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 16 Jan 2020 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No - EMA PRAC 3 Oct 2019 PRAC signal: New information on the known risk of breast cancer
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.